We are live on ! Find out more
LGND icon

Ligand Pharmaceuticals
LGND

116 hedge funds and large institutions have $640M invested in Ligand Pharmaceuticals in 2013 Q2 according to their latest regulatory filings, with 116 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

3% less call options, than puts

Call options by funds: $4.19M | Put options by funds: $4.33M

Holders
116
Holders Change
+116
Holders Change %
–
% of All Funds
3.79%
Holding in Top 10
5
Holding in Top 10 Change
+5
Holding in Top 10 Change %
% of All Funds
0.16%
New
116
Increased
–
Reduced
–
Closed
–
Calls
$4.19M
Puts
$4.33M
Net Calls
-$140K
Net Calls Change
-$140K

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
OAM
26
Oxford Asset Management
United Kingdom
$3.35M +$2.58M +143,308 New
Geode Capital Management
27
Geode Capital Management
Massachusetts
$3.31M +$2.55M +142,019 New
CP
28
Covalent Partners
Massachusetts
$3.28M +$2.53M +140,402 New
GGHC
29
Gilder Gagnon Howe & Co
New York
$3.2M +$2.47M +137,127 New
EI
30
EAM Investors
California
$2.97M +$2.29M +127,103 New
TCIM
31
TIAA CREF Investment Management
New York
$2.81M +$2.17M +120,502 New
RFC
32
Russell Frank Company
Washington
$2.78M +$2.14M +118,989 New
BBA
33
Baker Bros. Advisors
New York
$2.75M +$2.12M +117,660 New
Goldman Sachs
34
Goldman Sachs
New York
$2.57M +$1.98M +110,017 New
ARTA
35
A.R.T. Advisors
New York
$2.47M +$1.9M +105,870 New
B
36
Bailard
California
$2.43M +$1.87M +104,195 New
Ameriprise
37
Ameriprise
Minnesota
$2.03M +$1.56M +87,000 New
BCA
38
Benchmark Capital Advisors
New York
$1.98M +$1.53M +84,799 New
Morgan Stanley
39
Morgan Stanley
New York
$1.94M +$1.49M +82,958 New
Charles Schwab
40
Charles Schwab
California
$1.86M +$1.35M +74,921 New
KIA
41
Kopp Investment Advisors
Minnesota
$1.85M +$1.42M +79,155 New
BIM
42
BlackRock Investment Management
Delaware
$1.77M +$1.37M +75,982 New
BIM
43
Bogle Investment Management
Massachusetts
$1.65M +$1.28M +70,902 New
AllianceBernstein
44
AllianceBernstein
Tennessee
$1.43M +$1.1M +61,098 New
EWM
45
Evercore Wealth Management
New York
$1.36M +$1.05M +58,429 New
CS
46
Credit Suisse
Switzerland
$1.3M +$1,000K +55,579 New
EIM
47
Essex Investment Management
Massachusetts
$1.28M +$989K +54,986 New
SONJCPFA
48
State of New Jersey Common Pension Fund A
New Jersey
$1.21M +$932K +51,827 New
LCG
49
Lisanti Capital Growth
New York
$1.19M +$726K +40,388 New
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
$1.16M +$895K +49,764 New
1
2
3 4 5

LGND Hedge Fund Activity: Q2 2013 in Review

116 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q2 2013, worth a combined $640M.

Buyers outnumbered sellers: 116 funds opened new LGND positions and 0 closed out — a net gain of 116 holders — while 0 added to existing stakes and 0 trimmed.

  • 116 institutional investors held Ligand Pharmaceuticals (LGND) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $640M of Ligand Pharmaceuticals stock for Q2 2013.
  • 116 funds opened new Ligand Pharmaceuticals positions in Q2 2013 and 0 closed out, a net change of +116 holders.

Based on aggregated 13F filings for Q2 2013.